Related Experiment Videos

[Treatment of heart failure with calcium antagonists]

D Hall1, J Dirschinger, F Kraus

  • 1Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München.

Herz
|June 1, 1990
PubMed

Insights

Calcium channel blockers can treat heart failure, but their use depends on left ventricular function. Verapamil may worsen severe heart failure due to its negative inotropic effects.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Vasodilators are established treatments for congestive heart failure.
  • Calcium channel blockers (CCBs) are considered for heart failure, especially when ischemic heart disease is the cause.
  • Left ventricular dysfunction affects 60-70% of heart failure patients, often due to ischemic heart disease.

Purpose:

  • To evaluate the hemodynamic effects of calcium channel blockers in heart failure patients.
  • To determine the balance between negative inotropy and vasodilation from CCBs.
  • To identify patient subgroups who may benefit or experience adverse effects from CCBs.

Summary:

  • CCB administration results in opposing hemodynamic actions: negative inotropy and systemic vasodilation with sympathetic stimulation.
  • The net effect depends on the patient's cardiovascular status; mild dysfunction may tolerate negative inotropy, while severe dysfunction can deteriorate.
  • Verapamil has the strongest negative inotropic effect; benefits are seen with ejection fraction 30-40% and pulmonary capillary pressure ~20 mm Hg, beyond which heart failure may worsen.

Impact:

  • CCBs require careful patient selection in heart failure management.
  • Understanding the hemodynamic balance is crucial for optimizing CCB therapy.
  • Identifying thresholds for adverse effects guides clinical decision-making for verapamil in heart failure.

Related Concept Videos